Neural correlates of belief‐ and desire‐reasoning in 7‐ and 8‐year‐old children: an event‐related potential study

Theory of mind requires belief‐ and desire‐understanding. Event‐related brain potential (ERP) research on belief‐ and desire‐reasoning in adults found mid‐frontal activations for both desires and beliefs, and selective right‐posterior activations only for beliefs. Developmentally, children understand desires before beliefs; thus, a critical question concerns whether neural specialization for belief‐reasoning exists in childhood or develops later. Neural activity was recorded as 7‐ and 8‐year‐olds ( N  = 18) performed the same diverse‐desires, diverse‐beliefs, and physical control tasks used in a previous adult ERP study. Like adults, mid‐frontal scalp activations were found for belief‐ and desire‐reasoning. Moreover, analyses using correct trials alone yielded selective right‐posterior activations for belief‐reasoning. Results suggest developmental links between increasingly accurate understanding of complex mental states and neural specialization supporting this understanding. Theory of mind requires belief‐ and desire‐understanding. Event‐related brain potential (ERP) research on belief‐ and desire‐reasoning in adults found mid‐frontal activations for both desires and beliefs, and selective right‐posterior activations only for beliefs. Developmentally, children understand desires before beliefs; thus, a critical question concerns whether neural specialization for belief‐reasoning exists in childhood or develops later. Neural activity was recorded as 7‐ and 8‐year‐olds ( N  = 18) performed the same diverse‐desires, diverse‐beliefs, and physical control tasks used in a previous adult ERP study.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/93540/1/j.1467-7687.2012.01158.x.pd

An exploration of concepts of community through a case study of UK university web production

The paper explores the inter-relation and differences between the concepts of occupational community, community of practice, online community and social network. It uses as a case study illustration the domain of UK university web site production and specifically a listserv for those involved in it. Different latent occupational communities are explored, and the potential for the listserv to help realize these as an active sense of community is considered. The listserv is not (for most participants) a tight knit community of practice, indeed it fails many criteria for an online community. It is perhaps best conceived as a loose knit network of practice, valued for information, implicit support and for the maintenance of weak ties. Through the analysis the case for using strict definitions of the theoretical concepts is made

Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, cross-over study

<p>Abstract</p> <p>Background</p> <p>The purpose of the present investigation was to determine the effects of EPA/DHA supplementation on resting and exercise-induced inflammation and oxidative stress in exercise-trained men. Fourteen men supplemented with 2224 mg EPA+2208 mg DHA and a placebo for 6 weeks in a random order, double blind cross-over design (with an 8 week washout) prior to performing a 60 minute treadmill climb using a weighted pack. Blood was collected pre and post exercise and analyzed for a variety of oxidative stress and inflammatory biomarkers. Blood lactate, muscle soreness, and creatine kinase activity were also measured.</p> <p>Results</p> <p>Treatment with EPA/DHA resulted in a significant increase in blood levels of both EPA (18 ± 2 μmol·L^-1vs. 143 ± 23 μmol·L^-1; p < 0.0001) and DHA (67 ± 4 μmol·L^-1vs. 157 ± 13 μmol·L^-1; p < 0.0001), while no differences were noted for placebo. Resting levels of CRP and TNF-α were lower with EPA/DHA compared to placebo (p < 0.05). Resting oxidative stress markers were not different (p > 0.05). There was a mild increase in oxidative stress in response to exercise (XO and H₂O₂) (p < 0.05). No interaction effects were noted. However, a condition effect was noted for CRP and TNF-α, with lower values with the EPA/DHA condition.</p> <p>Conclusion</p> <p>EPA/DHA supplementation increases blood levels of these fatty acids and results in decreased resting levels of inflammatory biomarkers in exercise-trained men, but does not appear necessary for exercise-induced attenuation in either inflammation or oxidative stress. This may be due to the finding that trained men exhibit a minimal increase in both inflammation and oxidative stress in response to moderate duration (60 minute) aerobic exercise.</p

A resource of potential drug targets and strategic decision‐making for obstructive sleep apnoea pharmacotherapy

ABSTRACT There is currently no pharmacotherapy for obstructive sleep apnoea (OSA) but there is no principled a priori reason why there should not be one. This review identifies a rational decision‐making strategy with the necessary logical underpinnings that any reasonable approach would be expected to navigate to develop a viable pharmacotherapy for OSA. The process first involves phenotyping an individual to quantify and characterize the critical predisposing factor(s) to their OSA pathogenesis and identify, a priori, if the patient is likely to benefit from a pharmacotherapy that targets those factors. We then identify rational strategies to manipulate those critical predisposing factor(s), and the barriers that have to be overcome for success of any OSA pharmacotherapy. A new analysis then identifies candidate drug targets to manipulate the upper airway motor circuitry for OSA pharmacotherapy. The first conclusion is that there are two general pharmacological approaches for OSA treatment that are of the most potential benefit and are practically realistic, one being fairly intuitive but the second perhaps less so. The second conclusion is that after identifying the critical physiological obstacles to OSA pharmacotherapy, there are current therapeutic targets of high interest for future development. The final analysis provides a tabulated resource of ‘druggable’ targets that are relatively restricted to the circuitry controlling the upper airway musculature, with these candidate targets being of high priority for screening and further study. We also emphasize that a pharmacotherapy may not cure OSA per se, but may still be a useful adjunct to improve the effectiveness of, and adherence to, other treatment mainstays

Architectures and Design Methodologies for Scalable and Sustainable Remote Laboratory Infrastructures

With the increasing demand for distance learning opportunities in the higher education sector, there isan ever-growing need for the design and deployment of remote laboratories, especially for engineering,science, and technology curricula. In order to accommodate the offering of entire degrees for distancelearning students whose curricula require remote laboratories, scalable information technology infrastructuresthat support the large scale use and deployment of these remote laboratories must exist. Thischapter provides a discussion of architectures and design methodologies using technology such as commandand control communications, Web 2.0, and cloud computing, which provide a scalable, manageable,and sustainable technological infrastructure-basis for large scale remote laboratory deployment

Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study

Background: Clinical trials demonstrated that women treated for breast cancer with anthracycline or trastuzumab are at increased risk for heart failure and/or cardiomyopathy (HF/CM), but the generalizability of these findings is unknown. We estimated real-world adjuvant anthracycline and trastuzumab use and their associations with incident HF/CM. Methods We conducted a population-based, retrospective cohort study of 12 500 women diagnosed with incident, invasive breast cancer from January 1, 1999 through December 31, 2007, at eight integrated Cancer Research Network health systems. Using administrative procedure and pharmacy codes, we identified anthracycline, trastuzumab, and other chemotherapy use. We identified incident HF/CM following chemotherapy initiation and assessed risk of HF/CM with time-varying chemotherapy exposures vs no chemotherapy. Multivariable Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) with adjustment for age at diagnosis, stage, Cancer Research Network site, year of diagnosis, radiation therapy, and comorbidities. Results: Among 12 500 women (mean age &#x003D; 60 years, range &#x003D; 22–99 years), 29.6% received anthracycline alone, 0.9% received trastuzumab alone, 3.5% received anthracycline plus trastuzumab, 19.5% received other chemotherapy, and 46.5% received no chemotherapy. Anthracycline and trastuzumab recipients were younger, with fewer comorbidities than recipients of other chemotherapy or none. Compared with no chemotherapy, the risk of HF/CM was higher in patients treated with anthracycline alone (adjusted HR &#x003D; 1.40, 95% CI &#x003D; 1.11 to 1.76), although the increased risk was similar to other chemotherapy (adjusted HR &#x003D; 1.49, 95% CI &#x003D; 1.25 to 1.77); the risk was highly increased in patients treated with trastuzumab alone (adjusted HR &#x003D; 4.12, 95% CI &#x003D; 2.30 to 7.42) or anthracycline plus trastuzumab (adjusted HR &#x003D; 7.19, 95% CI &#x003D; 5.00 to 10.35). Conclusions: Anthracycline and trastuzumab were primarily used in younger, healthier women and associated with increased HF/CM risk compared with no chemotherapy. This population-based observational study complements findings from clinical trials on cancer treatment safety

Evolutionary development of the plant and spore wall

The article provides an overview of the development and structure of spore and pollen walls in the major plant groups and summarises progress in our understanding of the molecular genetics underpinning spore/pollen evolution and development

Effect of Dupilumab on Sleep Apnea Severity in Patients With Chronic Rhinosinusitis

Patients with chronic rhinosinusitis (CRS) report improved sleep quality after dupilumab, an anti IL4/13 therapy. Concurrent CRS and obstructive sleep apnea (OSA) cases are not rare, and CRS seemingly raises nasal resistance. Thus, we hypothesized that improved sleep quality by dupilumab therapy in CRS patients might be due to lowered nasal resistance and subsequent improvement of unrecognized comorbid OSA. Patients with concurrent CRS and OSA were recruited. Nasal resistance was measured invasively with transnasal pressure and flow data collected during normal respiration in the supine position. Results from the first five participants did not support our hypothesis. Subjective and objective measures for CRS and nasal resistance values were improved with dupilumab therapy in CRS patients with nasal polyps. However, apnea severity and sleep-related subjective parameters did not change. In the patients with CRS without nasal polyps, no significant changes in either CRS or OSA-related measures were observed